Previous close | 0.0310 |
Open | 0.0320 |
Bid | 0.0310 x 194091900 |
Ask | 0.0320 x 380640100 |
Day's range | 0.0300 - 0.0320 |
52-week range | 0.0150 - 0.0720 |
Volume | |
Avg. volume | 3,094,865 |
Market cap | 74.603M |
Beta (5Y monthly) | 2.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings date | 25 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Actinogen Medical Limited ( ASX:ACW ) shareholders will doubtless be very grateful to see the share price up 50% in the...
Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tomography (PET) study, confirming high levels of Xanamem target occupancy in the brain at safe, well tolerated, and biologically active doses, has been published in the Journal of Alzheimer's Disease.
Actinogen Medical Limited (ASX: ACW) announces that enrolment in the XanaCIDD Phase 2a proof-of-concept trial in 160 participants with cognitive impairment associated with persistent major depressive disorder (MDD) now exceeds 50 percent (that is, more than 80 participants enrolled to date). Results remain on track for release in the second quarter of 2024.